logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Introduction of Cyclofem once-a-month injectable contraceptive in Mexico.

    Article - En anglais

    A large introductory study of Cyclofem, a once-a-month injectable contraceptive, was conducted in three Mexican provinces.

    A total of 3457 healthy women participated : 640 women from rural areas (community-based component) and 2817 women from urban and suburban areas (health center-based component).

    A total of 20,316 women-months of treatment experience were accumulated during a one year period.

    Cyclofem proved its use-effectiveness (pregnancy rate of 0.03%) and its safety under routine service conditions of family planning facilities in Mexico.

    The overall life table continuation rate at 1 year was 26.1%. Higher continuation rates were observed in the community-based component (36.6%) as compared to the health center component (23. 7%). The most common reason for method discontinuation was change of address.

    Only 15% of the discontinuations were attributable to the injectable contraceptive method, with the overall 1 year discontinuation rate for bleeding problems (including amenorrhea) was<11%. These observations underscore the importance of appropriate counseling and follow-up measures, providing convenient access to repeat injections, and other service delivery issues related to continuation of Cyclofem.

    The results of this trial have once again demonstrated that Cyclofem is a highly effective method with an acceptable side effect profile. (...)

    Mots-clés Pascal : Médroxyprogestérone, Oestrogène, Progestatif, Oestroprogestatif, Contraceptif, Forme libération contrôlée, Voie intramusculaire, Mensuel, Suspension, Contraception, Homme, Femelle, Mexique, Amérique Centrale, Amérique, Epidémiologie, Planning familial, Facteur sociodémographique, Cipionate d'estradiol, Méthode combinée

    Mots-clés Pascal anglais : Medroxyprogesterone, Estrogen, Progestagen, Estroprogestagen, Contraceptive, Controlled release form, Intramuscular administration, Monthly, Suspension, Contraception, Human, Female, Mexico, Central America, America, Epidemiology, Family planning, Sociodemographic factor

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0452407

    Code Inist : 002B20A01. Création : 25/01/1999.